Home > Insider Trading > Filing (0001181431-14-010850)

Filing Details

Accession Number:: 0001181431-14-010850
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-03-05 06:13:05
Reporting Period:: 2014-03-03

Filing Date:: 2014-03-05
Accepted Time:: 2014-03-05 06:13:05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1386858	Hyperion Therapeutics Inc	HPTX	Pharmaceutical Preparations (2834)	611512713

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1202793	Michael Powell	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	No	No	Yes	No
1245624	James Healy	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	Yes	No	Yes	No
1362314	Eric Buatois	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	No	No	Yes	No
1380734	P L Vii Partners Venture Sofinnova	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	No	No	Yes	No
1421501	Sofinnova Management Vii, L.l.c.	C/O Sofinnova Ventures 2800 Sand Hill Road, Suite 150 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-03-03	590,000	$0.00	2,357,221	No	4	J	Indirect	See footnote
Common Stock	Acquisiton	2014-03-03	23,625	$0.00	23,625	No	4	J	Indirect	See footnote
Common Stock	Disposition	2014-03-04	23,625	$30.02	0	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Indirect	See footnote
No	4	J	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,855	Direct

Footnotes

Shares disposed of by way of distribution to the partners of Sofinnova Venture Partners VII, L.P. ("SV VII") pro rata and without consideration, in accordance with its partnership agreement and a Rule 10b5-1 Distribution Plan adopted by it on December 13, 2013, as amended (the "Distribution").
The shares are owned directly by SV VII. Sofinnova Management VII, L.L.C. ("SV VII LLC"), the general partner of SV VII, and James Healy, a director of the Issuer, Michael Powell, and Eric Buatois, the managing members of SV VII LLC, may be deemed to have shared voting and dispositive power over the shares owned by SV VII. Such persons and entities disclaim beneficial ownership over the shares owned by SV VII except to the extent of any pecuniary interest therein.
Shares acquired by SV VII LLC in connection with the Distribution of such shares to the partners of SV VII.
The shares are owned directly by SV VII LLC. James Healy, a director of the Issuer, Michael Powell, and Eric Buatois, the managing members of SV VII LLC, may be deemed to have shared voting and dispositive power over the shares owned by SV VII LLC. Such persons and entities disclaim beneficial ownership over the shares owned by SV VII LLC except to the extent of any pecuniary interest therein.
Shares disposed of in accordance with a Rule 10b5-1 Sales Plan adopted by SV VII LLC on December 16, 2013, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.70 to $30.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
The common stock was issued on March 8, 2012 upon the early exercise of an option that was immediately exercisable in full upon grant. One quarter of the shares vested on April 15, 2012, and the remainder of the shares vest at a rate of 1/36th per month thereafter. All exercised but unvested shares are subject to a repurchase right by the Issuer.
The shares are owned directly by Mr. Healy.